TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Online Support for Diabetes Self-Management

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Men and women 18 years to 80 years~* Current diagnosis of Type 2 Diabetes diagnosed at least 6 months previous to the intervention~* Have seen their participating family physician of the Vancouver Coastal Health Authority catchment area at least twice over the last two years, with at least one of those visits including the code for diabetes.~* English Speaking~* Ability to review the consent form independently~* Have access to the online video teleconsultation and personal health record from their home~* Have basic computer literacy (use a computer and the internet at least once a week)~Exclusion criteria:~* Physical disability that precludes normal internet use~* Diagnosis of a terminal illness~* Pregnancy, planning a pregnancy, or currently lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Online Support (Type: EXPERIMENTAL): 3 months online support, including access to online personal health record and 2.5 hours of online video teleconsultations with certified health professionals

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Detection of Bladder Tumors After 30 Min Instillation of Hexvix

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~The patients should be indicated for a transurethral resection of the bladder (TURB) based on an outpatient cystoscopy and fulfil the following inclusion criteria:~* Patients with multiple bladder tumors, defined as ≥2 lesions, based on an outpatient cystoscopy.~* Patients with known urinary urge symptoms or patients who have problems or pain holding back the urine for a time longer than 30 minutes.~* Age 18 years or above~Exclusion Criteria:~* Patients with known tumors in the prostatic urethra or distal urethra~* Gross haematuria. (Note: Gross haematuria is defined as a heavy bladder bleed resulting in marked amounts of blood in the urine, which may interfere with fluorescence cystoscopy. Where the bleed is light, the patient should not be excluded if in the investigator's opinion, rinsing during cystoscopy will alleviate the possible interference with fluorescence cystoscopy).~* Patient with porphyria.~* Hypersensitivity to the active substance or to any of the excipients of the solvent~* Participation in other clinical studies with investigational drugs either concurrently or within the last 30 days.~* Women of child-bearing potential meaning that only post-menopausal women, women who had their ovaries removed, and women who are otherwise physically unable to bear children can be included.~* Patients who have received BCG or chemotherapy within three months prior to study inclusion.~* Conditions associated with a risk of poor protocol compliance.~* Patient is the investigator or any sub investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol~* Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the clinical study.~* Patients unlikely to comply with protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* At least 18 years old~* Subjects must be hospitalized and have the following:~  * proven or high suspicion of SARS-CoV-2 infection and,~ * requiring oxygen supplementation defined as:~ * SpO2 ≤ 92% regardless of supplemental oxygen (ie on room air or on oxygen), or~ * SpO2 ≥ 92% on supplemental O2 and in the opinion of the Investigator it is not safe to decrease or remove the supplemental oxygen~ * require supplemental oxygen of no more than 10 L/minute, and~ * radiologic suspected or proven COVID-19 pneumonitis (chest x-ray or CT scan)~* Female subjects must have a negative pregnancy test~* Willing and able to comply with the treatment schedule and study procedures~Exclusion Criteria:~* Participating in another clinical trial of an investigational treatment for COVID-19~* Methemoglobin \> 3%~* Evidence of severe multi organ failure~* Use of assisted ventilation prior to initiation of iNO~* Pregnancy or positive pregnancy test pre-dose~* Open tracheostomy~* Chronic use of a nitric oxide donor agent such as nitroglycerin or drugs known to increase methemoglobin such as lidocaine, prilocaine, benzocaine, nitroprusside, isosorbide, or dapsone at screening~* History or clinical evidence of systolic heart failure, left ventricular dysfunction (LVEF \<40%)~* Subjects reporting massive hemoptysis associated with the current illness or with radiologically proven pulmonary embolus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Inhaled Nitric Oxide (iNO) (Type: ACTIVE_COMPARATOR): Pulsed inhaled iNO 125 mcg/kg IBW/hour
- Placebo (Type: SHAM_COMPARATOR): Pulsed inhaled N2, 99.999% gas

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Tegarderm® Placement for Bag Mask Ventilation in the Bearded Patient

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with perioral facial hair \>5mm in length~* Undergoing elective non-cardiac surgery with planned bag-mask ventilation during anesthesia induction~Exclusion Criteria:~* Known allergy to Tegaderm product and/or its adhesive~* Emergency surgery~* Active or unstable cardiac disease~* ASA (American Society of Anesthesiologists) physical status ≥4~* External or internal active airway obstruction from tumor, abscess, or laryngeal edema~* Organic or non-organic oropharyngeal anatomical defects including history of radiation treatment to the neck~* Moderate to severe acute and chronic restrictive or obstructive lung diseases, e.g. chronic obstructive pulmonary disease, asthma, etc.~* Requirement for rapid sequence intubation, or known aspiration risk~* Cervical spine injury~* Previously documented difficult mask ventilation or intubation~* BMI ≥50~* Vulnerable populations: children, prisoners, pregnant patients, cognitively impaired adults

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bag-Mask Ventilation with Tegaderm (Type: EXPERIMENTAL): Patients will receive bag-mask ventilation with Tegaderm placement
- Bag-Mask Ventilation without Tegaderm (Type: ACTIVE_COMPARATOR): Patients will receive bag-mask ventilation without Tegaderm placement

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~Individuals eligible to participate in this study must meet the following key criteria and additional criteria as specified in the protocol:~1. Male or female, aged ≥ 18 years~2. Confirmed diagnosis of MM per IMWG criteria~3. Measurable disease as defined by one or more of the following:~   * Serum M-protein ≥ 0.5 g/dL~  * Urine M-protein ≥ 200 mg/24 hours~  * Serum Free Light Chain (FLC) assay: involved FLC level ≥ 10 mg/dL provided serum FLC ratio is abnormal~  * In cases where SPEP is unreliable, serum quantitative immunoglobulin (qIgA) ≥ 750 mg/dL (0.75 g/dL) is acceptable~4. Relapsed or refractory (Rajkumar, 2011) to 3 or more different prior lines of therapy for MM, including immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), chemotherapies, or monoclonal antibodies, and not a candidate for, or intolerant to established therapy known to provide clinical benefit.~5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1~6. Adequate organ and marrow function at Screening, as defined by the study protocol.~Key Exclusion Criteria:~1. Monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma, Waldenstrom's macroglobulinemia, or IgM myeloma~2. Active plasma cell leukemia (˃ 2.0 × 109/L circulating plasma cells by standard differential)~3. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)~4. Prior treatment directed to B-cell Activating Factor (BAFF; BLyS), B-cell Maturation Antigen (BCMA;TNFSF17) or Transmembrane Activator and CAML interactor (TACI; TNFSF13B), including antibodies or BCMA- or TACI-directed Chimeric Antigen Receptor (CAR)-T cell therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BION-1301 (Type: EXPERIMENTAL): BION-1301 will be administered once every 2 weeks as an intravenous (IV) infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D Deficiency and Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Serum 25-hydroxyvitamin D level \<20 ng/ml (\<50 nmol/L)~* Diagnosed with atopic dermatitis by a CHW pediatric dermatologist~* Age 1-18 years old~* Primary residence in Milwaukee County~* Moderate and severe atopic dermatitis (Severity Scoring of Atopic Dermatitis \[SCORAD\] score greater than 15)~* On clinic protocol treatment for their atopic dermatitis (desonide ointment twice daily for the face and groin, triamcinolone 0.1% ointment twice daily for other areas)

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Standard dose vitamin D (Type: ACTIVE_COMPARATOR): Treatment with cholecalciferol 400 IU daily at home.
- High dose vitamin D (Type: ACTIVE_COMPARATOR): Treatment with ergocalciferol 300,000 IU (6 capsules of 50,000 IU) as a single oral dose observed in clinic.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Single vs Double Epidural Catheter Analgesia for Scoliosis Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients undergoing surgery via a posterior approach for AIS~2. Children ages 11-18~3. ASA physical status 1-2~4. Informed consent by legal guardian and assent by patient (for minors 11-17 years of age) or informed consent by subject (for patients 18 years of age)~5. Planned correction of at least 8 vertebral levels~Exclusion Criteria:~1. Patient refusal to participate~2. Patients on chronic narcotic medication~3. Allergy to standard of care drugs used in the study (Omnipaque, ropivacaine, hydromorphone, oxycodone, acetaminophen, gabapentin, ondansetron, nalbuphine or diphenhydramine, diazepam)~4. Coagulopathy~5. Pre-existing neurological deficit~6. Inability to use a Numerical Rating Scale (NRS: 0-10 patient self-reported score) for pain assessment

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- single epidural catheter (Type: ACTIVE_COMPARATOR): None
- double epidural catheter (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dietary Polyphenols and Glycation in Renal Insufficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* type 2 Diabetes Mellitus~* chronic renal insufficiency with persistent eGFR of 35-60mL/min for at least three months~* fluent in English~Exclusion Criteria:~* dialysis therapy (current or previous)~* malignancy~* transplant recipient~* hyperthyroidism~* hypothyroidism~* high dose glucocorticoids (≥250 mg)~* body mass index (BMI) ≥ 45 kg/m2~* special dietary requirements~* take creatine, antioxidants or vitamin supplements~* smoker~* pregnant~* consume \>4 cups of tea/coffee per day~* consume \>5 portion of fruits and vegetables per day

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Treatment group (Type: EXPERIMENTAL): Chlorogenic Acid (CGA) 400mg/day (CGA-enriched coffee)
- Control group (Type: SHAM_COMPARATOR): Conventional coffee (habitual diet)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Controlled Pilot Study to Assess Soft Tissue Reaction at the Crestal Part of a Dental Implant With ESTA Surface

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have voluntarily signed the informed consent form before any study related action~* Males and females must be at least 18 years of age and not more than 80 years old.~* Partially edentulous in posterior (position 3-7) maxilla or mandible with implants planned for single crowns in an area with a healed extraction socket.~* Adequate bone quality and quantity at the implant site to permit the insertion of a Straumann Soft Tissue Level implant of 4.1mm diameter without augmentation (at least 1mm bone buccally and lingually/palatal)~Exclusion Criteria:~* Oral surgery contraindicated according to the judgement of the investigator (should be explained in the CRF)~* Local inflammation, including untreated periodontitis~* Patients with inadequate oral hygiene or unmotivated for adequate home care. Full mouth plaque index \> 25% at time of surgery~* Presence of conditions requiring chronic routine prophylactic use of antibiotics (e.g., history of rheumatic heart disease, bacterial endocarditis, cardiac valvular anomalies, prosthetic joint replacements)~* Major systemic diseases~* Medical conditions requiring prolonged use of steroids~* Current pregnancy or breastfeeding women~* Physical handicaps that would interfere with the ability to perform adequate oral hygiene~* Use of any investigational drug or device within the 90 day period immediately prior to implant surgery on study day 0~* Alcoholism or chronically drug abuse~* Smokers; more than 10 cigarettes per day~* Immuno-compromised patients~* Conditions or circumstances, in the opinion of the investigator, which would prevent completion of study participation or interfere with analysis of study results, such as history of non-compliance, or unreliability.~Secondary Exclusion Criteria:~* GBR procedures at or adjacent to the planned study site~* Lack of primary stability of the dental implant at site of interest (e.g., rotational movement of the implant at a minimum of 15 Ncm torque at connection of the healing abutment, or tactile mobility)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Standard Plus ESTA STL Roxolid implant (Type: EXPERIMENTAL): This arm will receive the Straumann Soft Tissue Level Standard Plus Implant Ø 4.1 mm Regular Neck, SLActive® Roxolid, with a modified surface of the neck (ESTA).
- Standard Plus STL implant (Type: ACTIVE_COMPARATOR): This arm will receive the Straumann Soft Tissue Level Standard Plus Implant Ø4.1mm Regular Neck,SLActive® Titanium grade IV, with a machined surface of the neck.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Loratadine for Improvement of Bone Pain in Patients With Chronic Granulocyte-Colony Stimulating Factor (G-CSF) Use

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of neutropenia~* Granulocyte-colony stimulating factor (G-CSF) use for at least 3 months at least 4 times per month~* Mean bone pain of at least a 2/10 as assessed by questions 3-6 of the Brief Pain Inventory (BPI)~Exclusion Criteria:~* Other sources of chronic pain~* Previously tried loratadine for 7 consecutive days or more for bone pain~* Allergy to loratadine~* Chronic daily usage of antihistamine without an acceptable alternative non-antihistamine medication

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Loratadine first (Type: EXPERIMENTAL): Take treatment daily for 7 days.
- Placebo first (Type: PLACEBO_COMPARATOR): Take placebo daily for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: 5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with melanoma and determined, by their physician, to be appropriate for DecisionDx-Melanoma testing and who have successful results available to the investigator are eligible for registration~* Patients enrolled should be reasonably able to follow-up with the enrolling physician at regular intervals for assessment of outcome data.~* 16 Years and older~Exclusion Criteria:~* Less than 16 Years of age

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Rapid Pleurodesis Through an Indwelling Pleural Catheter

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of MPE as defined by~   1. A diagnosis a pleural effusion in the setting of known malignancy. AND~  2. Confirmed malignant involvement of the pleural space by fluid cytology or pleural biopsy. OR~  3. Evidence of pleural disease on radiographic imaging. OR~  4. A recurrent effusion with no other identifiable cause after thorough workup.~2. Symptomatic from the pleural effusions (shortness of breath, cough, or chest pain)~3. Prior thoracentesis with post procedure symptomatic relief~4. Recurrence of symptoms with re-accumulation of pleural effusion~5. Lung re-expansion after thoracentesis on chest imaging within last 30 days~Exclusion Criteria:~1. Malignant pleural effusion due to a hematologic malignancy~2. ECOG \>4~3. Any history of trapped lung~4. Prior attempted pleurodesis on the affected site~5. Age \<18~6. Pregnant or lactating~7. Known allergy to iodopovidone (Betadine)~8. Unable or unwilling to provide consent~9. Uncorrectable coagulopathy (INR \> 1.5, aPTT \> 1.5 x the upper limit of normal) or thrombocytopenia (\< 50,000)~10. Anatomic contraindication to IPC (overlying skin abnormalities)~11. Unable or unwilling to care for IPC and adhere to drainage protocol~12. Need for bilateral IPC placement

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of care (Type: PLACEBO_COMPARATOR): Subjects in this arm will receive placebo only (100mL of normal saline) into the pleural space delivered via the newly placed tunneled intrapleural catheter
- Rapid pleurodesis protocol (Type: EXPERIMENTAL): Subjects in this arm will receive the chemical pleurodesing agent of 10% iodopovidone solution delivered to the pleural space via the newly placed tunneled intrapleural catheter

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues